CD25 deficiency
Overview
CD25 deficiency is a rare autosomal recessive immunodeficiency disorder characterized by the absence or dysfunction of the interleukin-2 receptor alpha chain (IL-2R_), also known as CD25. This condition leads to impaired immune system function, resulting in increased susceptibility to infections and autoimmune disorders.

Pathophysiology
CD25 is a component of the high-affinity interleukin-2 receptor complex, which is crucial for the proliferation and survival of T cells. In CD25 deficiency, the lack of functional IL-2R_ impairs the signaling pathways necessary for T cell activation and regulatory T cell (Treg) development. This results in a compromised immune response and a failure to maintain immune tolerance, leading to autoimmunity.
Clinical Presentation
Patients with CD25 deficiency typically present in early childhood with recurrent infections, lymphadenopathy, and failure to thrive. Autoimmune manifestations may include autoimmune hemolytic anemia, immune thrombocytopenic purpura, and type 1 diabetes mellitus.
Diagnosis
The diagnosis of CD25 deficiency is based on clinical evaluation, laboratory findings, and genetic testing. Laboratory tests often reveal low or absent CD25 expression on T cells, reduced Treg numbers, and impaired T cell proliferation in response to IL-2. Genetic testing can confirm mutations in the IL2RA gene, which encodes the IL-2R_ chain.
Treatment
Management of CD25 deficiency involves supportive care, including prophylactic antibiotics to prevent infections and immunosuppressive therapy to control autoimmune symptoms. Hematopoietic stem cell transplantation (HSCT) may be considered in severe cases to restore immune function.
Prognosis
The prognosis for individuals with CD25 deficiency varies depending on the severity of the condition and the success of treatment interventions. Early diagnosis and appropriate management can improve outcomes and quality of life.
Related Pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian